Background: Despite the increasing use of robotic distal gastrectomy (RDG) in patients with gastric cancer (GC), its safety and efficacy compared to those of laparoscopic distal gastrectomy (LDG) have not been elucidated in a randomized controlled trial (RCT). We aimed to evaluate the short-term outcomes of patients with GC who received RDG or LDG. Methods: Three hundred patients with cT1-4a and N0/+ between September 2017 and January 2020 were enrolled in this RCT at a high-volume hospital in China. The short-term outcomes were compared between the groups.

No abstract

Background: Surufatinib (S, a small-molecule inhibitor of VEGFR1-3, FGFR1 and CSF-1R) plus toripalimab (T, an anti-PD-1 antibody) showed encouraging antitumor activity in solid tumors. Here, we report the results of 3 cohorts of advanced G/GEJ adenocarcinoma, ESCC and NEC of an ongoing, multi-cohort, phase 2 study of S + T (NCT04169672).Methods: Patients (pts) with histologically confirmed G/GEJ adenocarcinoma or advanced/metastatic ESCC or advanced NEC who progressed after 1L systemic chemotherapy were enrolled in cohorts A, B, C, respectively. Eligible pts received 21day cycles of S (250 mg orally QD) plus T (240 mg IV, Q3W). The primary endpoint was objective response rate (ORR) per RECIST 1.1.

significantly lower in EP compared to patients aged <70 years (5.5 vs 13 months (m) HR 3.86; IC 2.073-7.214; P < 0.0001). Progression-free survival (PFS) was significantly worse for EP than for younger patients (1.8 vs 3.6m, HR 2.1; IC 1.181 -3.744; P ¼ 0.012). Regarding toxicity, 30.6% irAEs were reported. There were no statistically significant differences in terms of irAEs between EP and younger patients (P ¼ 0.535). The development of irAEs was associated with better PFS in younger patients (13.3 vs 5.5m, HR 0.45; IC 0.244 -0.840; P ¼ 0.012) without significant impact on OS.

No abstract